Department of Dermatology, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Immunotherapy. 2023 Oct;15(15):1249-1256. doi: 10.2217/imt-2023-0081. Epub 2023 Aug 10.
Immune checkpoint inhibitors such as anti-PD-1 receptor antibodies have been shown to be effective in patients with advanced gastric cancer. However, there is a growing concern about immune-related adverse events. A case of a patient with gastric adenocarcinoma who developed toxic epidermal necrolysis (TEN) induced by sintilimab and subsequently developed lichenoid dermatitis is reported. TEN was diagnosed according to a history of sintilimab use, clinical symptoms and physical examination. During hospitalization, the patient developed recurrent fever caused by bacteremia and recovered from TEN after anti-infection and anti-inflammatory treatments. However, when TEN was controlled, the patient developed the lesional manifestations of lichenoid dermatitis. To date, no cases of lichenoid dermatitis after TEN have been reported following the use of PD-1 inhibitors.
免疫检查点抑制剂，如抗 PD-1 受体抗体，已被证明对晚期胃癌患者有效。然而，人们越来越关注免疫相关不良反应。报告了一例使用信迪利单抗后发生中毒性表皮坏死松解症（TEN）并随后发生类扁平苔藓样皮炎的胃腺癌患者。TEN 根据信迪利单抗使用史、临床症状和体格检查诊断。住院期间，患者因菌血症反复发热，经抗感染和抗炎治疗后 TEN 痊愈。然而，当 TEN 得到控制时，患者出现了类扁平苔藓样皮炎的皮损表现。迄今为止，尚未报道 PD-1 抑制剂治疗后 TEN 后出现类扁平苔藓样皮炎的病例。
